These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28267080)

  • 21. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
    Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
    Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.
    Pastore S; Stocco G; Moressa V; Zandonà L; Favretto D; Malusà N; Decorti G; Lepore L; Ventura A
    Rheumatol Int; 2015 Apr; 35(4):619-27. PubMed ID: 25240429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk.
    Gellekink H; Blom HJ; den Heijer M
    Clin Chem Lab Med; 2007; 45(4):471-6. PubMed ID: 17439323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.
    Warren RB; Smith RL; Campalani E; Eyre S; Smith CH; Barker JN; Worthington J; Griffiths CE
    Br J Dermatol; 2009 Feb; 160(2):438-41. PubMed ID: 19016697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.
    Malik F; Ranganathan P
    Pharmacogenomics; 2013 Feb; 14(3):305-14. PubMed ID: 23394392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis.
    Chandran V; Siannis F; Rahman P; Pellett FJ; Farewell VT; Gladman DD
    J Rheumatol; 2010 Jul; 37(7):1508-12. PubMed ID: 20472929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.
    Qiu Q; Huang J; Lin Y; Shu X; Fan H; Tu Z; Zhou Y; Xiao C
    Medicine (Baltimore); 2017 Mar; 96(11):e6337. PubMed ID: 28296761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.
    Woo HI; Kim JA; Jung HA; Kim KK; Lee JY; Sun JM; Ahn JS; Park K; Lee SY; Ahn MJ
    Pharmacogenomics; 2015; 16(4):383-91. PubMed ID: 25823786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
    Galbiatti AL; Castro R; Caldas HC; Padovani JA; Pavarino EC; Goloni-Bertollo EM
    Tumour Biol; 2013 Dec; 34(6):3765-71. PubMed ID: 23838799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling.
    Li M; Jin C; Xu M; Zhou L; Li D; Yin Y
    Cell Commun Signal; 2017 Dec; 15(1):52. PubMed ID: 29246230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis.
    Huang J; Fan H; Qiu Q; Liu K; Lv S; Li J; Yang H; Shu X; Xu Y; Lu X; Lu C; Zhang Y; Xiao C
    Ther Adv Chronic Dis; 2020; 11():2040622320916026. PubMed ID: 32426102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
    Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
    Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.
    Schmeling H; Biber D; Heins S; Horneff G
    J Rheumatol; 2005 Sep; 32(9):1832-6. PubMed ID: 16142884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
    Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
    Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR Are Related to the Outcome of Methotrexate Therapy for Rheumatoid Arthritis in a Chinese Population.
    Lv S; Fan H; Li J; Yang H; Huang J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Xiao C
    Front Pharmacol; 2018; 9():1390. PubMed ID: 30546311
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
    Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
    Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.